<h4>PURPOSE</h4><p>To assess the efficacy, predictability, and safety of LASIK for the surgical correction of low to moderate hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser.</p>
<h4>METHODS</h4><p>In a multicenter United States Food and Drug Administration (FDA) regulated study of LASIK, 7 centers enrolled 293 eyes with manifest refraction sphere that ranged from +0.50 to +6.00 diopters (D) with or without astigmatism up to 3.00 D. The intended outcome was plano in all eyes. Patients were treated bilaterally. One year postoperative outcomes are reported. </p>
<h4>RESULTS</h4><p>The mean spherical equivalent refraction (MRSE) for all eyes changed from +2.61±1.19 D (range: +0.50 to +6.63 D) preoperatively to +0.35±0.54 D (range: -1.63 to +2.00 D) 1 year postoperatively. Overall, 61% (170/279) of eyes achieved distance uncorrected visual acuity (UCVA) of 20/20 or better, 82% (228/279) of eyes saw 20/25 or better, and 99% (277/279) of eyes saw 20/40 or better. Refractive accuracy was demonstrated as 63.1% (176/279) of eyes achieved a MRSE within ±0.50 D and 90.3% (252/279) of eyes within ±1.00 D. Less than 2% (4/279) of eyes lost 2 lines of distance best spectacle-corrected visual acuity. Stability of refraction was demonstrated by 6 months, with a mean hyperopic shift of <0.03 D from 3 to 6 months. </p>
<h4>CONCLUSIONS</h4><p>The NIDEK EC-5000 corrected hyperopia and hyperopic astigmatism with UCVA, refractive accuracy, 1-year stability, and safety that surpassed all FDA criteria. [<cite>J Refract Surg.</cite> 2008;24:123-136.]</p>
<h4>ABOUT THE AUTHORS</h4>
<p>From InView, Atlanta, Ga (Waring); Clinical Research Consultants Inc, Cincinnati, Ohio (Fant); Sound Eye and Laser, Seattle, Wash (Phillips); Fischer Laser Eye Center, Willmar, Minn (Fischer); Liberty Laser Eye Center, Vienna, Va (Tanchel); Southern Eye Associates, Memphis, Tenn (Schanzer); the Department of Ophthalmology, Loma Linda University, Loma Linda, Calif (Narvaez); and CODET/Aris Vision Institute, Tijuana, BC, Mexico (Chayet).</p>
<p>Dr Waring is a consultant for NIDEK, AMO, Acufocus, Calhoun Vision, and SCHWIND. Dr Chayet is a consultant for NIDEK and Calhoun Vision. Dr Fant is a consultant for NIDEK and has a financial interest in Clinical Research Consultants Inc. The remaining authors have no financial interest in the materials presented herein.</p>
<p>Correspondence: George O. Waring III, MD, InView, 301 Perimeter Center North, Ste 600, Atlanta, GA 30346. Tel: 678.222.5102; Fax: 404.250.9006; E-mail: <a href="mailto:drgeorge@georgewaring.com">drgeorge@georgewaring.com</a></p>
<p>Received: June 25, 2007</p>
<p>Accepted: December 4, 2007</p>